Kyorin Rejects Sawai's Merger Proprosal, Leaving Japan's Generics Leader Scrambling Ahead Of Big Pharma Competition
This article was originally published in PharmAsia News
Executive Summary
TOKYO - In what amounted to a long-weekend consideration, Kyorin Pharmaceutical has rejected Sawai Pharmaceutical's proposal to initiate merger talks, adding a sense of urgency for the generics manufacturer as it tries to find business solutions to fend off generics competition in Japan from major pharma companies